HopeStage
Back to all studies
CompletedNCT00208819

Antipsychotic treatment alone or with divalproex for dementia-related agitation

About this titleRead the official source — NCT00208819
Medication studyAges 65+United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 65 years.

Listed locations
AtlantaSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2003
Recruitment status
Completed
Enrollment listed in the registry
50
Sponsor
Emory University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 65 Years
Official registry ID
NCT00208819
Official title
Show the full official title

Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Atlanta

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Emory University, a university.

Did this study involve medication?

Yes. The study involved medication, including risperidone, quetiapine, olanzapine and divalproex.

Who was this study for?

Listed age limits: from 65 years.

Want to explore more studies?

Explore studies